Mayo Foundation for Medical Education and Research

Buck Institute for Research on Aging

Unity Biotechnology, Inc.

Johns Hopkins University

Albert Davalos

Nathaniel E David

Judith Campisi

Remi-Martin Laberge

Marco Demaria

James L Kirkland

Tamar Tchkonia

Yi Zhu

Alain Philippe Vasserot

Jennifer H Elisseeff

Chaekyu Kim

Okhee Jeon

Jan M A Van Deursen

Darren J Baker

Bennett G Childs

Jan M Van Deursen

Jan Ma Van Deursen

Nathaniel David

Jennifer Elisseeff

Jan MA Van Deursen

Methods are provided herein for selectively killing senescent cells and for treating senescence-associated diseases and disorders by administering a senolytic agent. Senescence-associated diseases and disorders treatable by the methods using the senolytic agents described herein include cardiovascular diseases and disorders associated with or caused by arteriosclerosis, such as atherosclerosis; idiopathic pulmonary fibrosis; chronic obstructive pulmonary disease; osteoarthritis; senescence-associated ophthalmic diseases and disorders; and senescence-associated dermatological diseases and disorders.

Treating cardiovascular disease by selectively eliminating senescent cells

Foamy macrophages with senescence markers accumulate in the subendothelial space at the onset of atherosclerosis where they drive pathology by increasing expression of key atherogenic and inflammatory cytokines and chemokines. In advanced lesions, senescent cells promote features of plaque instability, including elastic fiber degradation and fibrous cap thinning, by heightening metalloprotease production. This invention provides methods and materials for treating arthritis by removing senescent cells in or around atherosclerotic plaques, thereby stabilizing the plaques, inhibiting rupture of the plaques and pathological sequelae that manifest as coronary artery disease.

Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques

Method of optimizing conditions for selectively removing a plurality of senescent cells from a tissue or a mixed cell population

This disclosure provides a technology for managing the sensation of pain in a subject in need thereof. Treatment methods according to this invention include administering to the subject a formulation that contains an effective amount of (4-[(4S,5R)-4,5-bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone).

Treatment of joint pain

Treatment for osteoarthritis in a joint by administering a means for inhibiting MDM2

Treatment for osteoarthritis by intra-articular administration of a cis-imidazoline

Unit dose of a cis-imidazoline for treating an osteoarthritic joint by removing senescent cells

Growing community of inventors

San Rafael, CA, United States of America

Albert Davalos